Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis

G. Y. Wang, S. L. Rayner, R. Chung, B. Y. Shi*, X. J. Liang

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)
87 Downloads (Pure)


Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that affects both upper and lower motor neurons, which results in loss of muscle control and eventual paralysis [1]. Currently, there are as yet unresolved challenges regarding efficient drug delivery into the central nervous system (CNS). These challenges can be attributed to multiple factors including the presence of the blood-brain barrier (BBB), blood-spinal cord barrier (BSCB), as well as the inherent characteristics of the drugs themselves (e.g. low solubility, insufficient bioavailability/bio-stability, 'off-target' effects) etc. As a result, conventional drug delivery systems may not facilitate adequate dosage of the required drugs for functional recovery in ALS patients. Nanotechnology-based strategies, however, employ engineered nanostructures that show great potential in delivering single or combined therapeutic agents to overcome the biological barriers, enhance interaction with targeted sites, improve drug bioavailability/bio-stability and achieve real-time tracking while minimizing the systemic side-effects. This review provides a concise discussion of recent advances in nanotechnology-based strategies in relation to combating specific pathophysiology relevant to ALS disease progression and investigates the future scope of using nanotechnology to develop innovative treatments for ALS patients.

Original languageEnglish
Article number100055
Pages (from-to)1-18
Number of pages18
JournalMaterials Today Bio
Publication statusPublished - 4 May 2020

Bibliographical note

Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


  • Amyotrophic lateral sclerosis (ALS)
  • Blood-brain barrier
  • Central nervous system (CNS)
  • Nanotechnology
  • Neurodegenerative diseases


Dive into the research topics of 'Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this